Nicholas Peterson

Eliaz Therapeutics (ETI), founded by Dr. Isaac Eliaz, focuses on harnessing his extensive expertise in Galectin-3 and Apheresis technology to create a cutting-edge therapeutic Apheresis device. This device aims to remove Galectin-3 from the bloodstream, which plays a pivotal role in various severe health conditions, particularly in Sepsis. Galectin-3 is linked to the exacerbation of inflammatory responses and immune dysregulation, including cytokine storms, which are critical factors in the progression and severity of sepsis. The primary application of this technology is targeted at treating sepsis and its common complication, sepsis-induced Acute Kidney Injury (SA-AKI). Sepsis is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. In the United States alone, sepsis leads to millions of hospitalizations each year, with a significant number of these cases progressing to AKI. This condition complicates the course of sepsis by impairing kidney function, potentially necessitating intensive treatments like dialysis or kidney transplantation. Currently, there are no approved treatments that effectively prevent, alleviate, or expedite recovery from sepsis and its associated AKI. ETIs XGAL3 apheresis technology offers a potential breakthrough in sepsis treatment, aiming to improve patient management and outcomes dramatically, and offering hope for saving hundreds of thousands of lives each year.

RAD Intel is a technology company that revolutionizes brand engagement using advanced language models to understand audience interests and behaviors, facilitating precise content strategy and delivery. Its award-winning technology helps reduce bias, ensuring impactful messaging that maximizes content performance and marketing ROI.

Fathom summarizes your Zoom, Google Meet or Microsoft Teams meetings so you can focus on the conversation instead of taking notes.

We’re the Robinhood for pre-IPO startups. Everyone can angel invest $100 in a Community Round. On May 16, 2016, it became legal for everyday people to invest as little as $100 in startups and small businesses. Since then, we’ve helped 1,860 founders raise almost $500M from their community - for flying cars, coffee shops, and everything in between. We’re a Public Benefit Corporation with a mission to revitalize capitalism and keep the American dream alive. GDP growth is slowing. Wealth inequality is increasing. Entrepreneurship is dying across America; falling from 10.6% to 3.6% among those under 30 since 1989. We’re reversing these trends by funding more deserving businesses across all of America, not solely tech startups in Silicon Valley. Want to help? Join us! We’re a team of founder types: enjoy autonomy, responsibility, the opportunity to learn, and no red tape. Just make it happen.

Neurocarrus is developing a novel therapy to treat pain without addiction. We are a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control. Our first-in-class therapeutic (N-001) is designed to treat the physiological symptoms of pain without invasive surgical procedures or systemically absorbed drugs. We engineered N-001 for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute nerve damage. N-001 is a leading technology in the fight against the prescription opioid abuse and heroin epidemic, which claims the lives of tens of thousands of Americans each year. A safe, non-addictive and effective treatment for pain (a disease burden of over $635 billion in the US*) would have a major impact on human health. Neurocarrus was founded by prominent research scientists in the field of protein engineering. The company is led by a strong management and advisory team with expertise in business, biotechnology and medicine. To date, we have generated extensive in vitro and in vivo data supporting the efficacy of N-001.

The JOBS Act (passed in 2012 and enacted in 2016) allows all Americans to invest in startups, which was previously limited to only the wealthy elite. Now, thousands of everyday investors put millions of dollars into startups every year. Despite that, there is still no research and analytics solutions similar to the public market (e.g., Morningstar, Bloomberg, SeekingAlpha, The Motley Fool) to empower individuals to make informed investment decisions. Kingscrowd aims to empower everyone to invest in startups confidently through a suite of products including research, ratings, data analytics, founder interviews, and financial products. Kingscrowd collects hundreds of data points on every startup that raises money online, and our patent-pending algorithm provides a quantitative assessment of the startups investment potential. We believe in the power of data-driven investment decisions.

StartEngine is one of the leading equity crowdfunding platforms in the U.S., where everyday people can find and invest in early-growth companies and startups, as well as a variety of alternative assets and collectibles. StartEngine has hosted over 1,100 successful funding rounds between Reg. CF and Reg. A+ combined through StartEngine’s funding portal and broker dealer, from a community of over 1,000,000 strong. Based in Los Angeles, the company was created in 2014 by Howard Marks, co-founder of Activision, and Ron Miller. Were hiring: https://www.startengine.com/careers Invest in startups and build your portfolio. www.startengine.com For accredited investors – exclusive investment opportunities from some of todays largest privately held companies. www.startengine.com/private **“StartEngine" refers to StartEngine Crowdfunding, Inc. StartEngine operates 5 wholly owned subsidiaries, StartEngine Capital, LLC, StartEngine Primary, LLC, StartEngine Secure, LLC, StartEngine Private LLC, and StartEngine Assets, LLC. Unless otherwise indicated, Regulation Crowdfunding offerings are offered through StartEngine Capital LLC, an SEC-registered funding portal and FINRA member; brokerage services, including Regulation A+ and Regulation D offerings, brokerage accounts, and securities trading through StartEngine Secondary (a SEC-regulated alternative trading system, operated by StartEngine Primary, LLC), are offered through StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC; and transfer agent services are offered through StartEngine Secure, LLC, an SEC registered transfer agent. StartEngine Assets LLC is an asset manager for StartEngine Collectibles Fund I LLC which offers Regulation A+ offerings in collectibles (e.g., fine art, wine) through the StartEngine platform.

Eliaz Therapeutics (ETI), founded by Dr. Isaac Eliaz, focuses on harnessing his extensive expertise in Galectin-3 and Apheresis technology to create a cutting-edge therapeutic Apheresis device. This device aims to remove Galectin-3 from the bloodstream, which plays a pivotal role in various severe health conditions, particularly in Sepsis. Galectin-3 is linked to the exacerbation of inflammatory responses and immune dysregulation, including cytokine storms, which are critical factors in the progression and severity of sepsis. The primary application of this technology is targeted at treating sepsis and its common complication, sepsis-induced Acute Kidney Injury (SA-AKI). Sepsis is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. In the United States alone, sepsis leads to millions of hospitalizations each year, with a significant number of these cases progressing to AKI. This condition complicates the course of sepsis by impairing kidney function, potentially necessitating intensive treatments like dialysis or kidney transplantation. Currently, there are no approved treatments that effectively prevent, alleviate, or expedite recovery from sepsis and its associated AKI. ETIs XGAL3 apheresis technology offers a potential breakthrough in sepsis treatment, aiming to improve patient management and outcomes dramatically, and offering hope for saving hundreds of thousands of lives each year.

Cytonics is a research and development company dedicated to discovering and developing therapeutics based on the protease inhibitor Alpha2 Macroglobulin (A2M). We are developing a number of A2M therapies with the goal of out-licensing the drugs to strategic partners at the key clinical value inflection points. We maximize the value of the drugs we discover by putting them in the hands of leading pharmaceutical companies with late-stage development, commercialization and marketing expertise. As a result of this strategy, we keep our organization focused with a strong financial position. We have discovered a unique “bio-marker” that can assist physicians in improving patient outcomes by pinpointing the source of orthopedic pain. We are also developing a range of therapeutic products for the treatment of painful osteoarthritis, back, and joint pain. Cytonics has a research lab located in Jupiter, FL with a team of scientists and PhD’s, working to discover and develop products for the treatment of musculoskeletal disease. Our Mission is to be the leader in diagnostic products for musculoskeletal disease, and to develop highly effective biotechnology based treatments for back and joint pain.

RAD Intel is a technology company that revolutionizes brand engagement using advanced language models to understand audience interests and behaviors, facilitating precise content strategy and delivery. Its award-winning technology helps reduce bias, ensuring impactful messaging that maximizes content performance and marketing ROI.

Fathom summarizes your Zoom, Google Meet or Microsoft Teams meetings so you can focus on the conversation instead of taking notes.

We’re the Robinhood for pre-IPO startups. Everyone can angel invest $100 in a Community Round. On May 16, 2016, it became legal for everyday people to invest as little as $100 in startups and small businesses. Since then, we’ve helped 1,860 founders raise almost $500M from their community - for flying cars, coffee shops, and everything in between. We’re a Public Benefit Corporation with a mission to revitalize capitalism and keep the American dream alive. GDP growth is slowing. Wealth inequality is increasing. Entrepreneurship is dying across America; falling from 10.6% to 3.6% among those under 30 since 1989. We’re reversing these trends by funding more deserving businesses across all of America, not solely tech startups in Silicon Valley. Want to help? Join us! We’re a team of founder types: enjoy autonomy, responsibility, the opportunity to learn, and no red tape. Just make it happen.